StockData

Zhengye Biotechnology Holding Ltd (ZYBT) stock

ZYBTNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026Score 4/30
$1.48−0.04 (-2.63%)

Close on Nov 20, 2026Market cap $70.14MP/E –Yield –

Zhengye Biotechnology free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was CN¥12.33M, down 55.1% from the year before.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025CN¥12.33M-55.1%
FY2024Dec 31, 2024CN¥27.46M-32.7%
FY2023Dec 31, 2023CN¥40.79M–
FY2022Dec 31, 2022-CN¥9.99M–

More Zhengye Biotechnology figures

See a number that looks wrong?